Education
About Us
Working with TipRanks
Follow Us
Affimed N.V. (GB:0HL9)
:0HL9
0HL9 Stock Chart & Stats
$0.02
-$0.14(-10.33%)
At close: 4:00 PM EST
$0.02
-$0.14(-10.33%)
Day’s Range― - ―
52-Week Range$0.02 - $4.00
Previous CloseN/A
Volume52.99K
Average Volume (3M)2.31K
Market Cap
$1.52K
Enterprise ValueN/A
Total Cash (Recent Filing)$24.94M
Total Debt (Recent Filing)$12.89M
Price to Earnings (P/E)―
Beta2.43
Next Earnings
Nov 18, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 15, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding15,227,463
10 Day Avg. Volume28
30 Day Avg. Volume2,312
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Potential OpportunitiesUpcoming presentation at a major oncology meeting presents a potential opportunity to attract partners or funding.
Bears Say
Insolvency ProceedingsAffimed announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany.
Liquidity ConcernsThere is substantial doubt about the company's ability to continue as a going concern due to liquidity conditions.
Affimed News
0HL9 FAQ
What was Affimed N.V.’s price range in the past 12 months?
Affimed N.V. lowest share price was $0.02 and its highest was $4.00 in the past 12 months.
What is Affimed N.V.’s market cap?
Affimed N.V.’s market cap is $1.52K.
When is Affimed N.V.’s upcoming earnings report date?
Affimed N.V.’s upcoming earnings report date is Nov 18, 2025 which is in 24 days.
How were Affimed N.V.’s earnings last quarter?
Currently, no data Available
Is Affimed N.V. overvalued?
According to Wall Street analysts Affimed N.V.’s price is currently Overvalued.
Does Affimed N.V. pay dividends?
Affimed N.V. pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Affimed N.V. dividends here
What is Affimed N.V.’s EPS estimate?
Affimed N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Affimed N.V. have?
Affimed N.V. has 15,227,463 shares outstanding.
What happened to Affimed N.V.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Affimed N.V.?
Currently, no hedge funds are holding shares in GB:0HL9
Company Description
Affimed N.V.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Technical Analysis
Entero Therapeutics
―
Evaxion Biotech
―
Bolt Biotherapeutics
―
GRI Bio
―
SAB Biotherapeutics
―
Options Prices
Currently, No data available
---